Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women

2003312 citationsJournal Articlebronze Open Access

Authors

J.F.R. Robertson · Nottingham City Hospital

C. Kent Osborne · Methodist Hospital

Anthony Howell · Cancer Research UK

Stephen E. Jones · Texas Oncology

L. Mauriac · Institut Bergonié

Matthew J. Ellis · Vince Lombardi Cancer Clinic

Ulrich R. Kleeberg

Abstract

Fulvestrant was tolerated well and was at least as effective as anastrozole in the second-line treatment of patients with ABC. This new hormonaltherapy may provide a valuable treatment option for ABC in postmenopausal women.

Topics & Keywords

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Cancer

Volume 98, Issue 2, pp. 229-238

DOI: 10.1002/cncr.11468

Field-Weighted Citation Impact: 12.49